Loading
A melanoma pioneer who led the vemurafenib and cobimetinib trials and now heads Victoria's cancer alliance.
Grant McArthur is Executive Director of the Victorian Comprehensive Cancer Centre Alliance and a melanoma medical oncologist at the Peter MacCallum Cancer Centre in Melbourne. He was a principal investigator for BRIM-3 and coBRIM, the trials that established BRAF inhibition with vemurafenib and combined BRAF and MEK inhibition with cobimetinib in melanoma. His publications include the extended follow-up of vemurafenib in BRAF V600E and V600K mutation-positive melanoma from BRIM-3. He has led translational programmes on resistance and on combining targeted therapy with immunotherapy, and now heads Victoria's cancer alliance.
| Title | Journal | Year |
|---|---|---|
| Safety and efficacy of vemurafenib in BRAF V600E and V600K mutation-positive melanoma (BRIM-3): extended follow-up | Lancet Oncology | 2014 |
| CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma | New England Journal of Medicine | 2025 |
Shares Cobimetinib, Vemurafenib.
Shares Cobimetinib, Vemurafenib.
Shares Vemurafenib, Melanoma.
Shares Vemurafenib, BRAF, Melanoma.
Shares Cobimetinib, Vemurafenib.
Shares Cobimetinib, Vemurafenib, BRAF, Melanoma.
Shares Peter MacCallum Cancer Centre, Melanoma.
Shares Cobimetinib, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/